Brachytherapy for the palliation of dysphagia owing to esophageal cancer: A systematic review and meta-analysis of prospective studies
- PMID: 28104297
- DOI: 10.1016/j.radonc.2016.12.034
Brachytherapy for the palliation of dysphagia owing to esophageal cancer: A systematic review and meta-analysis of prospective studies
Abstract
Background: The management of dysphagia owing to esophageal cancer is challenging. Brachytherapy has been proposed as an alternative option to stent placement. We performed a systematic review to examine its efficacy and safety in the resolution of dysphagia.
Methods: Prospective studies recruiting at least 20 patients with malignant dysphagia and published up to April 2016 were eligible. The dysphagia-free survival (DFS) and adverse event rates were pooled by means of a random effect model.
Results: Six studies for a total of 9 treatment arms (623 patients) were eligible for inclusion. After 1month since treatment, the DFS rate was 86.9% [95%CI: 76.0-93.3%]; after 3months, it was 67.2% [95%CI: 56.1-76.7%]; after 6months, it was 47.4% [95%CI: 38.5-56.5%]; after 9months, it was 37.6% [95%CI:30.0-45.9%]; and, finally, after 12months, it was 29.4% [95%CI: 21.6-38.7%]. The heterogeneity between studies was high at 1-, 3- and 6-month assessment; the values of I2 were 86.3%, 80.0% and 57.8%, respectively. The meta-regression analysis showed total radiation dose and number of fractions as the only positively influencing factors. Severe adverse event rate was 22.6% (95%CI 19.4-26.3). The main reported adverse events were brachytherapy-related stenosis (12.2%) and fistula development (8.3%). Two cases (0.3%) of deaths were reported due to esophageal perforation.
Conclusion: Brachytherapy is a highly effective and relatively safe treatment option therefore its underuse is no longer justified. Further studies should investigate the optimal radiation dose and number of fractions able to achieve the highest DFS rates.
Keywords: Brachytherapy; Dysphagia; Esophageal cancer.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
-
Radioactive self-expanding stents for palliative management of unresectable esophageal cancer: a systematic review and meta-analysis.Dis Esophagus. 2017 May 1;30(5):1-16. doi: 10.1093/dote/dow010. Dis Esophagus. 2017. PMID: 28375442
-
Role of Esophageal Metal Stents Placement and Combination Therapy in Inoperable Esophageal Carcinoma: A Systematic Review and Meta-analysis.Dig Dis Sci. 2018 Apr;63(4):1025-1034. doi: 10.1007/s10620-018-4957-z. Epub 2018 Feb 8. Dig Dis Sci. 2018. PMID: 29417326
-
Interventions for dysphagia in oesophageal cancer.Cochrane Database Syst Rev. 2009 Oct 7;(4):CD005048. doi: 10.1002/14651858.CD005048.pub2. Cochrane Database Syst Rev. 2009. Update in: Cochrane Database Syst Rev. 2011 Feb 16;(2):CD005048. doi: 10.1002/14651858.CD005048.pub3. PMID: 19821338 Updated.
-
Systematic review of brachytherapy for symptom palliation.Brachytherapy. 2022 Nov-Dec;21(6):912-932. doi: 10.1016/j.brachy.2022.07.008. Epub 2022 Sep 7. Brachytherapy. 2022. PMID: 36085137
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
Cited by
-
Efficacy and safety of self-expanding metal stents in patients with inoperable esophageal cancer: a real-life study.Ther Adv Gastrointest Endosc. 2023 Sep 26;16:26317745231200975. doi: 10.1177/26317745231200975. eCollection 2023 Jan-Dec. Ther Adv Gastrointest Endosc. 2023. PMID: 37771789 Free PMC article.
-
Endoluminal high-dose-rate brachytherapy for locally recurrent or persistent esophageal cancer.Brachytherapy. 2018 May-Jun;17(3):621-627. doi: 10.1016/j.brachy.2018.01.010. Epub 2018 Feb 26. Brachytherapy. 2018. PMID: 29496425 Free PMC article.
-
Proposed brachytherapy recommendations (practical implementation, indications, and dose fractionation) during COVID-19 pandemic.Brachytherapy. 2020 Jul-Aug;19(4):390-400. doi: 10.1016/j.brachy.2020.04.009. Epub 2020 May 1. Brachytherapy. 2020. PMID: 32423787 Free PMC article. No abstract available.
-
Palliation of dysphagia in patients with non-curable esophageal cancer - a retrospective Danish study from a highly specialized center.Support Care Cancer. 2022 Nov;30(11):9029-9038. doi: 10.1007/s00520-022-07316-8. Epub 2022 Aug 10. Support Care Cancer. 2022. PMID: 35947208
-
Effectiveness of several external beam radiotherapy schedules for palliation of esophageal cancer.Clin Transl Radiat Oncol. 2019 Apr 24;17:24-31. doi: 10.1016/j.ctro.2019.04.017. eCollection 2019 Jul. Clin Transl Radiat Oncol. 2019. PMID: 31193091 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous